Bryan Garnier & Cie Reiterates “Buy” Rating for AstraZeneca (AZN)
AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities researchers at Bryan Garnier & Cie in a research report issued on Monday, Stock Ratings Network.com reports. They currently have a GBX 3,620 ($58.08) price objective on the stock. Bryan Garnier & Cie’s price target points to a potential upside of 13.76% from the stock’s previous close.
Shares of AstraZeneca (LON:AZN) opened at 3157.00 on Monday. AstraZeneca has a 52 week low of GBX 2786.00 and a 52 week high of GBX 3544.50. The stock has a 50-day moving average of GBX 3215.42 and a 200-day moving average of GBX 3252.57. The company’s market cap is £39.526 billion.
A number of other firms have also recently commented on AZN. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday, October 1st. Separately, analysts at Leerink Swann raised their price target on shares of AstraZeneca from GBX 50 ($0.80) to GBX 51 ($0.82) in a research note to investors on Monday, September 30th. They now have a “market perform” rating on the stock. Finally, analysts at Panmure Gordon reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Monday, September 30th. They now have a GBX 3,200 ($51.34) price target on the stock. Eleven equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 3,098.10 ($49.70).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.